BeiGene Ltd. (ONC) experienced a significant 24-hour plunge of 6.86% in the night session, as President Trump's announcement to lower prescription drug costs sent shockwaves through the Asian pharmaceutical sector.
The decline comes in response to President Trump's declaration that he would sign an executive order implementing a "Most Favored Nation" policy. This policy aims to tie U.S. government drug prices to those paid by other countries, potentially affecting the profitability of pharmaceutical companies operating in the U.S. market.
BeiGene's sharp drop aligns with a broader trend observed across Asian drugmakers. Other major players in the region, including Daiichi Sankyo, Otsuka Holdings, and WuXi Biologics, also saw their shares decline. The market reaction underscores investors' concerns about the potential impact of U.S. drug pricing reforms on international pharmaceutical companies' revenues and profit margins.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。